NDA 207953 · Janssen Prods
Yondelis
Trabectedin · Intravenous · Alkylating Drug
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Oct 23, 2015
Approved uses
2
Original approval plus efficacy supplements
Registered trials
89
18 Phase 3, 12 recruiting
FAERS reports
2,350
2,142 serious, 464 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 6, 2026.
YONDELIS ® is indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] . YONDELIS is an alkylating drug indicated for the treatment of adult patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen ( 1 )
Mechanism: Trabectedin is an alkylating drug that binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix towards the major groove. Adduct formation triggers a cascade of events that can affect the subsequent activity of DNA binding proteins, including some transcription factors, and DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 29, 2018 Supplement 4 · Efficacy · priority review OrphanLabelLetterPediatric Medical Review
- Oct 23, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanSummary ReviewPediatric Clinical Pharmacology ReviewPediatric Written Request
1 products under this application
- YONDELIS · TRABECTEDIN 1MG/VIAL · POWDER, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Trabectedin" as an intervention, any sponsor and status, largest first.
- An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian CancerPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00113607 · 672 participants · Start Apr 2005 · Primary completion Nov 2010
Drug: Trabectedin; DOXIL and 1 more · For: Ovarian Cancer
Sites: Mobile, Alabama; Tucson, Arizona; Los Angeles, California · 111 sites in all
- INOVATYON STUDY -International, Randomized Study in Patients With Ovarian CancerPivotal-lookingCompleted
Mario Negri Institute for Pharmacological ResearchAcademic, hospital or other
NCT01379989 · 617 participants · Start Jun 2011 · Primary completion Dec 17, 2020
Drug: Carboplatin; Pegylated Lipoxomal Doxorubicin (PLD) and 1 more · For: Ovarian Cancer
Sites: Graz, Austria; Innsbruck, Austria; Vienna, Austria · 132 sites in all
- A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01846611 · 581 participants · Start Oct 16, 2013 · Primary completion Jan 18, 2018
Drug: Trabectedin; DOXIL and 2 more · For: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 138 sites in all
- A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or LeiomyosarcomaPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT01343277 · 579 participants · Start Jun 2011 · Primary completion Jan 2015
Drug: Trabectedin; Dacarbazine · For: Advanced Liposarcoma or Leiomyosarcoma
Sites: Phoenix, Arizona; Tucson, Arizona; Little Rock, Arkansas · 88 sites in all
- Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant ChemotherapyPivotal-lookingCompleted
Italian Sarcoma GroupResearch network
NCT01710176 · 550 participants · Start Jun 1, 2011 · Primary completion Jun 30, 2024
Drug: epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3); gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8) and 4 more · For: Localized High-risk Soft Tissue Sarcomas of the Extremities and Trunk Wall in Adults
Sites: Candiolo, Italy; Aviano (PN), Italy; Bologna, Italy · 15 sites in all
- A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)Pivotal-lookingRecruiting
Intensity Therapeutics, Inc.Industry
NCT06263231 · 333 participants (planned) · Start Jun 28, 2024 · Primary completion Dec 2027
Drug: INT230-6; Eribulin and 2 more · For: Sarcoma,Soft Tissue
Sites: Phoenix, Arizona; Los Angeles, California; Santa Monica, California · 20 sites in all
- A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced CancerPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00060944 · 271 participants · Start May 2003 · Primary completion May 2008
Drug: Yondelis; Yondelis and 2 more · For: Liposarcoma; Leiomyosarcoma
Sites: Los Angeles, California; Aurora, Colorado; Coeur d'Alene, Idaho · 39 sites in all
- SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaRecruiting
Sarcoma Oncology Research Center, LLCAcademic, hospital or other
NCT03138161 · 250 participants (planned) · Start Apr 13, 2017 · Primary completion Dec 31, 2030
Drug: Trabectedin; Ipilimumab and 1 more · For: Advanced Soft Tissue Sarcoma; Metastatic Soft Tissue Sarcoma
Sites: Santa Monica, California
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neutropenia251
- anaemia214
- nausea206
- thrombocytopenia202
- febrile neutropenia163
- pancytopenia161
- off label use154
- vomiting151
- disease progression139
- rhabdomyolysis132
- alanine aminotransferase increased125
- asthenia107
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2006 | 2 |
| 2007 | 7 |
| 2008 | 6 |
| 2009 | 4 |
| 2010 | 12 |
| 2011 | 44 |
| 2012 | 27 |
| 2013 | 28 |
| 2014 | 35 |
| 2015 | 82 |
| 2016 | 344 |
| 2017 | 254 |
| 2018 | 266 |
| 2019 | 213 |
| 2020 | 151 |
| 2021 | 132 |
| 2022 | 157 |
| 2023 | 153 |
| 2024 | 173 |
| 2025 | 127 |
| 2026 | 133 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Yondelis (Trabectedin)
2024 spending
$355K
Beneficiaries
n/a
42 claims
Per beneficiary
n/a
$3,352.03 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $258,465 |
| 2021 | $371,519 |
| 2022 | $109,538 |
| 2023 | $577,821 |
| 2024 | $355,315 |
Part B: Yondelis (Trabectedin) · HCPCS J9352
2024 spending
$16.1M
Beneficiaries
426
1,765 claims
Per beneficiary
$37,759
2024 ASP limit $348.74 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $9,458,687 |
| 2021 | $9,056,753 |
| 2022 | $11,938,777 |
| 2023 | $12,203,518 |
| 2024 | $16,085,534 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma.
Pautier P, Italiano A, Piperno-Neumann S, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial.
Pautier P, Italiano A, Piperno-Neumann S, et al. · Lancet Oncol 2022 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial.
Demetri GD, von Mehren M, Jones RL, et al. · J Clin Oncol 2016 · Clinical Trial, Phase III, Multicenter Study
- Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
Gronchi A, Ferrari S, Quagliuolo V, et al. · Lancet Oncol 2017 · Clinical Trial, Phase III, Comparative Study
- Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
Perez-Ruixo JJ, Zannikos P, Hirankarn S, et al. · Clin Pharmacokinet 2007 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J, Perez-Ruixo JJ, Stuyckens K, et al. · Clin Pharmacol Ther 2008 · Meta-Analysis
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.